Japan-based Solasia Pharma KK (TYO: 4597) announced that it will reduce its direct operations in China by transferring all promotion rights for two drugs to its existing partner, Lee’s Pharmaceutical Holdings Ltd (HKG: 0950). The move aims to enhance sales efficiency across the mainland China market.
Drugs Involved
The two drugs in question are Sancuso (granisetron transdermal patch), used for the prevention of chemotherapy-induced nausea and vomiting (CINV), and episil (sodium valproate), a liquid formulation for managing pain from oral mucositis associated with chemotherapy or radiotherapy. Both drugs were launched in mainland China in 2019.
Previous and New Arrangements
Since their launch, Solasia has been responsible for commercialization in Beijing, Shanghai, and Guangzhou, while Lee’s handled all other markets. Under the new agreement, Lee’s will take over distribution, promotion, and sales for the entire mainland China market. Solasia will continue to manufacture and supply the products to Lee’s Pharmaceutical. The new deal will take effect from August 1, 2022.-Fineline Info & Tech
